Old Web
English
Sign In
Acemap
>
Paper
>
Post-docetaxel survival in metastatic castration-resistant prostate cancer (mCRPC) is improving in the Netherlands
Post-docetaxel survival in metastatic castration-resistant prostate cancer (mCRPC) is improving in the Netherlands
2018
Hm Westgeest
M Kuppen
F. Van Den Eertwegh
J. Van Moorselaar
Niven Mehra
Jules L.L.M. Coenen
I.M. van Oort
F van den Bergh
Katja K. Aben
R. Somford
Andries M. Bergman
J. Lavalaye
C.A. Uyl-de Groot
Winald R. Gerritsen
Keywords:
Urology
Prostate cancer
Castration
Medicine
Docetaxel
castration resistant
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]